G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value

被引:11
|
作者
Cho, NH [1 ]
Lim, SY
Kim, YT
Kim, D
Kim, YS
Kim, JW
机构
[1] Yonsei Univ, Coll Med, Dept Pathol, Seoul 120749, South Korea
[2] Yonsei Univ, Coll Med, Dept Obstet & Gynecol, Seoul 120749, South Korea
[3] Yonsei Univ, Coll Med, Dept Biostat, Seoul 120749, South Korea
关键词
p53; polymorphism; G2; checkpoint; cyclin B1; p34(cdc2); SnaPshot;
D O I
10.1016/S0090-8258(03)00198-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction. We aimed to verify not only whether homozygous Arg at codon 72 of the p53 apoptotic domain is a possible risk factor for cervical human papillomavirus (HPV)-related cancer, but whether degraded p53 may have an effect on a G2 checkpoint of the cell cycle. The implication of the codon 72 polymorphism of p53 in cervical tumor remains controversial. Furthermore, G2 checkpoint alteration and its relationship with p53, the codon 72 allotype, according to HPV infection in cervical tumors, has not been studied. Materials and methods. The purified genomic DNA from 252 archival cervical tissues [102 cervical intraepithelial neoplasias (CINs) and 46 squamous cell carcinomas of the uterine cervix (SCCs), and 104 normal] were amplified by nested polymerase chain reaction (PCR) for HPV-16/HPV-18. In addition, all of them were amplified by PCR for exon 4 of p53, where the codon 72 resides. The amplified PCR products were then sequenced using the forward primer. A polymorphism analysis was done by SnaPshot ddNTP primer extension and following direct sequencing. The reaction mixture was treated with 0.25 unit of shrimp alkaline phosphatase (Amersham) at 37degreesC for 1 h, subsequently performed in an ABI Prism 310 Genetic Analyzer (Perkin-Elmer). The archival slides were incubated overnight at 4degreesC using mouse anti-human recombinant cyclin B 1 polyclonal antibody or mouse anti-Xenopus p34(cdc2) monoclonal antibody for immunohistochemistry (Santa Cruz Biotech, Santa Cruz, CA). Results. The frequency of Arg allelic homozygosity was high in both cases (89.1%) and the control (80.8%) group (P = 0.4703). All groups except CIN were in Hardy-Weinberg equilibrium. There was no significant difference in the frequency of p53 polymorphism between the HPV-positive (Arg, 88.0%) and the negative (Arg, 88.8%) groups, or between CIN (Arg, 88.2%) and SCC (Arg, 89.1%). Both immunoreactivities to cyclin B and p34(cdc2) were strongly correlated with the HPV infection (P = 0.0001) and the histological types (P 0.0001) between CIN and SCC, being strongly correlated with each other (alpha:0.62954, P = 0.0001). Conclusion. The particular type of the p53 polymorphism does not bear relation to the progression of cervical cancer, HPV infection, or to the p53 codon 72 polymorphism. However, the G2 checkpoint appears to be altered in the case of a HPV-positive SCC. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:15 / 22
页数:8
相关论文
共 50 条
  • [41] Human papilloma virus 16 E6 oncoprotein associated with p53 inactivation in colorectal cancer
    Tan-Hsia Chen
    Chi-Chou Huang
    Kun-Tu Yeh
    Shu-Hau Chang
    Shih-Wen Chang
    Wen-Wei Sung
    Ya-Wen Cheng
    Huei Lee
    World Journal of Gastroenterology, 2012, (30) : 4051 - 4058
  • [42] Human papillomavirus (HPV) type 18 E6 oncoprotein, like 16 E6, mediates cell cycle arrest in G2 phase.
    Toy, EP
    Day, S
    Rose, R
    Planelles, V
    JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2004, 11 (02) : 411A - 411A
  • [43] High expression of CCDC106 promotes cervical cancer cell proliferation and migration by p53 degradation despite the HPV16 E6 spliced status
    Cao, C.
    Zhi, W.
    Lin, S.
    Wu, P.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 188 - 188
  • [44] PinX1, a novel target gene of p53, is suppressed by HPV16 E6 in cervical cancer cells (vol 1839, pg 88, 2014)
    Wu, Gengze
    Liu, Dongbo
    Jiang, Ke
    Zhang, Li
    Zeng, Yijun
    Zhou, Peng
    Zhong, Dan
    Gao, Min
    He, Fengtian
    Zheng, Yingru
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2015, 1849 (03): : 367 - 367
  • [45] The clinical value of HPV E6/E7 and STAT3 mRNA detection in cervical cancer screening
    Fan, Yibing
    Shen, Zongji
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (05) : 767 - 775
  • [46] THE ROLE OF MIR-1246 IN THE PATHOGENESIS OF CERVICAL CANCER AND ITS RELATIONSHIP TO HPV16 E6
    Zhang, Y.
    Xu, Q. I. N. G.
    Yang, Y. U.
    Zhang, Y. I.
    Tian, Y. A. N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 762 - 762
  • [47] Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents
    Luo, Y
    Rockow-Magnone, SK
    Joseph, MK
    Bradner, J
    Butler, CC
    Tahir, SK
    Han, EKH
    Ng, SC
    Severin, JM
    Gubbins, EJ
    Reilly, RM
    Rueter, A
    Simmer, RL
    Holzman, TF
    Giranda, VL
    ANTICANCER RESEARCH, 2001, 21 (1A) : 23 - 28
  • [48] Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer
    Mohan, Anbuselvam
    Krishnamoorthy, Sneha
    Sabanayagam, Rajalakshmi
    Schwenk, Gregory
    Feng, Eric
    Ji, Hai-Feng
    Muthusami, Sridhar
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 957
  • [49] Chromatin relaxation by overexpression of mutant p53, HPV16-E6, or cyclin G transgenes
    Smith, ML
    Bortnick, RA
    Sheikh, MS
    Fornace, AJ
    EXPERIMENTAL CELL RESEARCH, 1998, 242 (01) : 235 - 243
  • [50] OLIGOMERIZATION OF FULL-LENGTH P53 CONTRIBUTES TO THE INTERACTION WITH MDM2 BUT NOT HPV E6
    MARSTON, NJ
    JENKINS, JR
    VOUSDEN, KH
    ONCOGENE, 1995, 10 (09) : 1709 - 1715